thybetaxor (CS060304) / Cascade Pharma - LARVOL DELTA

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Jun 2026

Enrollment closed • Trial completion date • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Not yet recruiting ➔ Recruiting | Trial primary completion date: Apr 2025 ➔ Nov 2025

Enrollment open • Trial primary completion date • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Cascade Pharmaceuticals, Inc | Initiation date: Aug 2024 ➔ Mar 2025

Trial initiation date • Metabolic Dysfunction-Associated Steatohepatitis

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Cascade Pharmaceuticals, Inc

New P1 trial • Metabolic Dysfunction-Associated Steatohepatitis